Tel: 01789 267520

Latest News: Research

UK Site Closed For The ISIS Trial In Patients With Spinal Muscular Atrophy Type 2

21 October 2015 / Posted in: Research

Professor Volker Straub, Principle Investigator, would like to inform you that Newcastle upon Tyne is no longer a trial site for the CHERISH clinical trial sponsored by ISIS pharmaceuticals. Find out more here.

Read full story

Biogen and Isis Pharmaceuticals provide community update on ISIS-SMNRx

08 October 2015 / Posted in: Research

Biogen and Isis Pharmaceuticals have published a letter to the SMA community about the clinical development of their antisense oligonucleotide drug, ISIS-SMNRx.

Read full story

Clinical Care Research Correspondent

25 September 2015 / Posted in: Research

We were delighted to appoint Dr. Alex Murphy to this new post on 1st September 2015.

Read full story

Talking to Scientists: SMA Type 2

25 September 2015 / Posted in: Research

Ben Morris, who has SMA Type 2, and his dad Doug, recently went to Switzerland to talk to scientists and researchers about the impact SMA has on their lives.

Read full story

SMA Support UK at the Cure SMA Conference 2015

16 September 2015 / Posted in: Research

Find out the latest research updates from the Cure SMA Conference which was held in Kansas City, Missouri, USA from 18th-20th June 2015.

Read full story

SMA Europe: Call for SMA Research Projects 2015

25 August 2015 / Posted in: Research

SMA Europe is pleased to announce its 8th International call for SMA Research Projects. The application deadline for projects is 9th December 2015.

Read full story

Oracle Fieldwork: New SMA Consultation

17 August 2015 / Posted in: Research

Families are being invited to test a questionnaire, from market research company Oracle Fieldwork, that may be used in the future in clinical settings such as hospitals and out-patient clinics.

Read full story

Isis pharmaceuticals announces latest update from ongoing Phase II Trial

16 June 2015 / Posted in: Research

ISIS Pharmaceuticals has provided an update on the latest results from its ongoing Phase II clinical trial of the gene therapy drug ISIS-SMNRx.

Read full story

Novartis identifies new SMN2 splice-modifying drug

16 June 2015 / Posted in: Research

Novartis has published new research that identifies a novel small molecule drug that is able to increase survival motor neuron (SMN) protein levels, and therefore has the potential to treat SMA.

Read full story

Non-invasive Prenatal diagnosis for selected gene disorders (NIPSIGEN)

09 June 2015 / Posted in: Research

You can read the research project team’s latest update here.

Read full story